levetiracetam + sodium valproate

Levetiracetam + sodium valproate is a combination of two antiepileptic drugs used primarily as adjunctive therapy in the management of epilepsy, particularly in patients with partial onset seizures, generalized seizures, and drug-resistant epilepsy. Levetiracetam is a pyrrolidone derivative that acts mainly by binding to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability. It may also inhibit N-type calcium channels and antagonize 5-hydroxytryptamine receptor 3A. Sodium valproate (valproic acid) increases gamma-aminobutyric acid (GABA) levels in the brain by inhibiting GABA transaminase and possibly blocking voltage-gated sodium channels, thereby stabilizing neuronal membranes. The combination has been shown to improve seizure control compared to monotherapy or other combinations, with a favorable safety profile and reduced incidence of adverse drug reactions[1][4][7]. This regimen is commonly used when monotherapy is insufficient for seizure control.

Other names

divalproex sodium + levetiracetamsodium valproate + levetiracetam